 Neoadjuvant Therapy
"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
| Descriptor ID |
D020360
|
| MeSH Number(s) |
E02.186.450
|
| Concept/Terms |
Neoadjuvant Therapy- Neoadjuvant Therapy
- Neoadjuvant Therapies
- Therapies, Neoadjuvant
- Therapy, Neoadjuvant
- Neoadjuvant Treatment
- Neoadjuvant Treatments
- Treatment, Neoadjuvant
- Treatments, Neoadjuvant
|
Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".
Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".
This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2004 | 2 | 0 | 2 | | 2005 | 3 | 1 | 4 | | 2006 | 1 | 4 | 5 | | 2007 | 1 | 3 | 4 | | 2008 | 4 | 3 | 7 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 5 | 6 | | 2011 | 3 | 3 | 6 | | 2012 | 4 | 4 | 8 | | 2013 | 2 | 6 | 8 | | 2014 | 3 | 4 | 7 | | 2015 | 2 | 3 | 5 | | 2016 | 3 | 14 | 17 | | 2017 | 4 | 14 | 18 | | 2018 | 6 | 9 | 15 | | 2019 | 9 | 14 | 23 | | 2020 | 13 | 14 | 27 | | 2021 | 8 | 19 | 27 | | 2022 | 7 | 13 | 20 | | 2023 | 5 | 20 | 25 | | 2024 | 11 | 18 | 29 | | 2025 | 6 | 13 | 19 | | 2026 | 7 | 6 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.
-
Halimi A, Zwart ES, Yilmaz BS, Kurlinkus B, Ahola R, Del Chiaro M, Sparrelid E, Rangelova E, Maggino L, Malleo G, Lionetto G, Salvia R, Roberts KJ, Giovinazzo F, Falconi M, Crippa S, Belfiori G, Kazemier G, Maisonneuve P, Laukkarinen J, Ceyhan GO. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Langenbecks Arch Surg. 2026 Sep 22; 411(1).
-
Isaacs C, Nanda R, Yau C, Chien AJ, Hershman DL, Stringer-Reasor EM, Wallace AM, Thomas A, Vaklavas C, Clark AS, Kennedy LC, Sanford A, Boughey JC, Albain KS, Pusztai L, Kalinsky KM, Beckwith H, Williams NO, Han HS, Falkson C, Arora M, Elias AD, Pohlmann PR, Rozenblit M, Marshall N, Chen YY, Trivedi MS, McGuinness JE, Howard FM, Chen N, Khoury K, Lancaster RB, Yeung KT, Douglas E, Wei M, Mainor C, LeStage B, Delson AL, Asare AL, Brown-Swigart L, Hirst GL, Matthews JB, Perlmutter J, Symmans WF, Yee D, Hylton NM, van 't Veer LJ, Rugo HS, DeMichele AM, Berry DA, Esserman LJ. Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2026 Sep 01; 12(9):1008-1017.
-
Tung N, Zhao F, DeMichele A, Prat A, Winer EP, Wright JL, Recht A, Weiss AC, Tjoe JA, Feldman SM, Rocque GB, Smith ML, O'Sullivan CC, Sardesai SD, Tang SC, Modi S, Irvin WJ, Unni N, Battelli C, Bagegni N, Krie AK, George MA, Telli ML, Borges VF, D'Abreo N, Shah P, Villagrasa P, Badve S, Partridge AH, Miller KD, Carey LA, Wolff AC. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR. J Clin Oncol. 2026 Oct 20; 44(30):2919-2928.
-
Omiya K, Oba A, Tanaka K, Miyazaki N, Otsuka S, Ohgi K, Sugiura T, Shintakuya R, Okada K, Uemura K, Yamaki S, Hashimoto D, Inoue K, Mizuma M, Unno M, Nakagawa N, Tanaka H, Takami H, Takeuchi S, Ito A, Akahoshi K, Ban D, Sugawara S, Takahashi R, Motoi F, Inoue Y, Takahashi Y, Hirano S, Satoi S. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. JAMA Surg. 2026 Aug 01; 161(8):805-815.
-
Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Álvarez-Fernández C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gómez de Liaño A. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026 Jul 23; 395(4):338-348.
-
Poletto E, Olthof PB, Ruzzenente A, Adam JP, Alwayn IPJ, Boleslawski E, de Boer MT, Chebaro A, Chiche L, Dopazo C, Dubbeld J, Erdmann JI, Hakeem A, Coenraad MJ, Kuipers H, Mabrut JY, Maulat C, Maithel SK, de Meijer VE, Mohkam K, Murad SD, Muscari F, Rolinger J, Polak WG, Rayar M, Ratti F, Robin F, Schnitzbauer AA, Sparrelid E, Van Vilsteren FGI, Porte RJ, Hoogwater FJH, Groot Koerkamp B. Outcomes of Liver Transplant Versus Partial Hepatectomy for Perihilar Cholangiocarcinoma Patients Requiring Arterial Reconstruction. Liver Int. 2026 07; 46(7):e70729.
-
Dacic S, Shenker D, Redman M, Brunner L, Saqi A, Cooper WA, Borczuk A, Chung JH, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, Brosnan-Cashman J, Hennek S, Grullon S, Posadas J, Fujimoto J, Connolly C, Wynes MW, Sanchez-Espiridion B, Lee JJ, Berezowska S, Chou TY, Kerr K, Nicholson AG, Schalper KA, Tsao MS, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn PA, Kris MG, Travis W, Yu L, Wistuba I. Machine Learning Assessment of Pathologic Response in Lung Cancer Resections After Neoadjuvant Therapy-IASLC MPR Project. J Thorac Oncol. 2026 Oct; 21(10):103953.
-
Wong EYT, Damle SR, Shiu KK, Cohen SA, Lieu CH. Immunotherapy in Localized Colorectal Cancer: Current Practice and Future Directions. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520600.
-
Molnár A, Rodriguez Franco S, Sugawara T, Croce C, Kirsch MJ, Svensson J, Stoop TF, Messersmith WA, Schulick RD, Franklin O, Del Chiaro M. Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer - A retrospective intention-to-treat analysis. HPB (Oxford). 2026 Jul; 28(7):932-944.
-
Wach MM, Bank H, Kelly K, Le T, Derby J, Nunns G, Zureikat AH, Bartlett DL, Ahrendt SA, Pingpank JF, Choudry HA, Ongchin M. A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC. Ann Surg Oncol. 2026 Jul; 33(7):6175-6184.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|